Ervin Eaker, MD
Gastroenterology · Shawnee, KSNPI 1427007764
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 616 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AbbVie at 26.4% of the total. Among gastroenterology clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 616 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Pfizer$1K
- Lilly USA, LLC$585
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$463
- plus $3K from 28 others
Across 72 payments — averaging $2273.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$90K
- Ironwood Pharmaceuticals, Inc$34K
- Eli Lilly$18K
- Pfizer$14K
- Bristol Myers Squibb$8K
- UCB Biosciences Inc.$800
What the payments were for
- Food & beverage$10,68599%
- Education$551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 185 | $2,831 |
| Johnson & Johnson | 85 | $1,725 |
| Takeda Pharmaceuticals U.S.A., Inc. | 81 | $1,458 |
| Pfizer | 74 | $1,060 |
| Lilly USA, LLC | 25 | $585 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 28 | $463 |
| Mauna Kea Technologies, Inc. | 13 | $373 |
| Bristol Myers Squibb | 19 | $305 |
| Merck | 19 | $292 |
| Regeneron Healthcare Solutions, Inc. | 8 | $237 |
| QOL Medical, LLC | 8 | $191 |
| Redhill Biopharma Inc. | 7 | $127 |
| Celltrion USA Inc. | 6 | $120 |
| Sanofi | 4 | $118 |
| Amgen | 6 | $115 |
| Phathom Pharmaceuticals, Inc. | 4 | $89 |
| Ironwood Pharmaceuticals, Inc | 6 | $86 |
| Ferring Pharmaceuticals Inc. | 5 | $84 |
| Intercept Pharmaceuticals, Inc. | 5 | $81 |
| Micro-tech Endoscopy USA, Inc. | 8 | $68 |
| Gilead | 3 | $44 |
| Nestle Healthcare Nutrition Inc. | 2 | $41 |
| Braintree Laboratories, Inc. | 3 | $40 |
| Organon | 1 | $35 |
| Sandoz | 1 | $23 |
| Biocon Biologics Inc | 1 | $22 |
| Ardelyx, Inc. | 1 | $20 |
| Romark Laboratories, LC | 1 | $18 |
| Boston Scientific | 1 | $18 |
| Alfasigma USA, Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Stryker | 1 | $15 |
| Endogastric Solutions, Inc | 2 | $8 |
How this compares
$10,740 in reported general payments places this provider in the 90th percentile of 98 gastroenterology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 23 | $623,413 |
| Colestipol Hcl | 18 | $4,291 |
| Pantoprazole Sodium | 409 | $2,741 |
| Lubiprostone | 13 | $1,472 |
| Sucralfate | 87 | $1,390 |
| Omeprazole | 31 | $610 |
| Famotidine | 60 | $540 |
| Dicyclomine Hcl | 24 | $316 |
| Metronidazole | 13 | $159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,725 | $623,41323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 98 gastroenterology providers in Kansas.
Other gastroenterology in Shawnee
- Scott PropeckShawnee$4K
- Michael ThompsonShawnee$3K
- Charles BrooksShawnee$3K
- Phani Ashok AttaluriOlathe$957K
- Ryan TaylorKansas City$241K
- Winston DunnKansas City$169K
- Francis DaileyLeawood$82K
- Rashmi TadiparthiKansas City$60K
- Prateek SharmaKansas City$47K
- Erica DaileyOverland Park$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.